Your session is about to expire
← Back to Search
Ociperlimab + Tislelizumab for Solid Cancers
Study Summary
This trial is testing a new combination cancer treatment to see how safe and effective it is. They will also be looking at what dose is tolerated or maximum administered dose.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer has spread to my brain or the covering of my brain.I have an autoimmune disease that is currently active or might come back.I am fully active or can carry out light work.I have been treated with drugs that target the immune system, except anti-PD(L)1 for a specific group.I am not currently on any strong infection treatments, except for liver cancer.I have received treatments targeting TIGIT before.My non-squamous NSCLC has specific genetic changes (EGFR, ALK, or ROS1).I have received treatment for cancer that came back or spread.I do not have active brain or spinal cord tumor spread.I have an advanced cancer that can't be removed by surgery and have tried or can't undergo standard treatment.My organs are functioning well.I have gastric cancer that is either squamous or HER2 positive.
- Group 1: Phase 1b Cohort 2
- Group 2: Phase 1b Cohort 4
- Group 3: Phase 1b Cohort 3
- Group 4: Phase1b Cohort 7
- Group 5: Phase 1b Cohort 5
- Group 6: Phase 1b Cohort10
- Group 7: Phase1b Cohort 9
- Group 8: Phase 1
- Group 9: Phase1b Cohort 6
- Group 10: Phase 1b Cohort 1
- Group 11: Phase1b Cohort 8
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has there been any precedent for research regarding BGB-A1217?
"Currently, there are 2187 clinical trials in progress exploring BGB-A1217. These studies span a total of 106615 sites with 662 being phase 3 trials taking place primarily in Guangzhou and surrounding areas within Guangdong."
What is the scope of subjects involved in this research?
"Affirmative, clinicaltrials.gov data suggests that this study is still open for recruitment, having been originally posted on August 26th 2019 and recently updated on May 16th 2022. The trial has a target of 542 individuals to be recruited from 19 different medical facilities."
What medical issues has BGB-A1217 been found to alleviate?
"BGB-A1217 has been demonstrated to remediate acute lymphoblastic leukemia (ALL), neoplasm metastasis, as well as metastatic ureter urothelial carcinoma."
Has the FDA sanctioned BGB-A1217 for clinical application?
"The safety of BGB-A1217 was rated at a 1 due to the minimal data available from Phase 1 trials, which is primarily used to evaluate its efficacy and security."
Is enrollment still open for this experiment?
"According to the clinicaltrials.gov portal, this investigation is actively seeking participants; it was initially advertised on August 26th 2019 and recently updated on May 16th 2022."
In how many distinct locales can this experiment be accessed?
"Mayo Clinic Arizona in Phoenix, Arizona, University of Miami Sylvester Comprehensive Cancer Center in Miami, New jersey and Rutgers-Cancer Institute of New Jersey in New Brunswick are just some of the 20 sites participating in this research study."
Share this study with friends
Copy Link
Messenger